Beta blockers and weight gain
Pro Research Analysisby 
Searched over 200M research papers
Beta Blockers and Weight Gain: A Comprehensive Analysis
Introduction to Beta Blockers and Weight Gain
Beta blockers are commonly prescribed medications for managing hypertension and other cardiovascular conditions. However, their use has been associated with weight gain, which can complicate the management of obesity and related metabolic disorders. This article synthesizes findings from multiple studies to provide a clear understanding of the relationship between beta blockers and weight gain.
Evidence of Weight Gain with Beta Blocker Use
Clinical Trials and Observational Studies
Several studies have documented weight gain in patients using beta blockers. A systematic analysis of eight randomized controlled trials found that patients on beta blockers experienced a median weight gain of 1.2 kg over six months compared to controls1. Similarly, another study highlighted that beta blockers could decrease metabolic rate by approximately 10%, contributing to weight gain2.
Specific Populations: Chronic Heart Failure and Diabetes
In patients with chronic heart failure (CHF), beta blockers were associated with an average weight gain of 0.9 kg over one year, particularly in those with milder symptoms (NYHA class I and II)3. In the GEMINI trial, patients with type 2 diabetes and hypertension treated with metoprolol gained significantly more weight (1.19 kg) compared to those treated with carvedilol5.
Age-Related Weight Gain
A study evaluating middle-aged and elderly patients found that those on beta blockers gained more weight compared to those on ACE inhibitors, particularly in the 50-69 age group4. This suggests that beta blockers may exacerbate age-related weight gain.
Mechanisms Behind Weight Gain
Metabolic Rate and Thermogenesis
Beta blockers reduce facultative thermogenesis, the body's ability to generate heat in response to stimuli, by 50-100 kcal/day. This reduction can lead to an annual weight gain of 2-5 kg10. Additionally, beta blockers can induce insulin resistance, further complicating weight management in patients with diabetes or predisposed to diabetes10.
Energy Metabolism
Beta blockers may negatively impact energy metabolism, making obesity management more challenging in hypertensive patients2. This is particularly concerning for overweight or obese patients, as beta blockers can hinder weight loss efforts.
Implications for Clinical Practice
Obesity and Hypertension Management
Given the propensity of beta blockers to cause weight gain, their use as first-line therapy in overweight or obese hypertensive patients should be reconsidered1 2. Alternative antihypertensive medications, such as ACE inhibitors, which have more favorable effects on weight, may be more appropriate4.
Special Considerations for Elderly Patients
In elderly populations, particularly those with hypertension, beta blockers like atenolol have been associated with higher rates of obesity compared to other beta blockers or no beta blocker use8 9. This highlights the need for careful selection of antihypertensive therapy in older adults to avoid exacerbating weight gain.
Conclusion
The association between beta blockers and weight gain is well-documented across various patient populations and clinical settings. The mechanisms include reduced metabolic rate and thermogenesis, as well as potential insulin resistance. Clinicians should consider these factors when prescribing beta blockers, especially for patients who are overweight, obese, or have diabetes. Alternative treatments may be more suitable to avoid the adverse metabolic effects associated with beta blockers.
Sources and full results
Most relevant research papers on this topic
Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis.
Beta-blockers may cause initial weight gain in obese hypertensive patients, making obesity management more challenging.
Meta-Analysis
Highly CitedUse of beta‐blockers in obesity hypertension: potential role of weight gain
Beta-blockers may cause weight gain in overweight hypertensive patients, making obesity management more challenging, questioning their use as first-line therapy.
Highly CitedBeta-blockers and weight change in patients with chronic heart failure.
Beta-blocker use and intensification of heart failure treatment is associated with weight gain in chronic heart failure patients, particularly in those without peripheral edema and with functional class I and II symptoms.
Observational StudyAntihypertensive medication with beta-blockers and ACE-inhibitors-effects on weight gain associated with ageing.
Beta-blocker therapy promotes weight gain more than ACE-inhibitor therapy in middle aged and elderly patients, while older patients show only a small increase in body weight.
Observational StudyBody weight changes with beta-blocker use: results from GEMINI.
Metoprolol tartrate is associated with increased weight gain compared to carvedilol, particularly in patients with hypertension and diabetes not taking insulin therapy.
Observational StudyEffect of beta-adrenergic blockade on weight changes in patients with chronic heart failure.
Beta-blocker therapy in patients with chronic heart failure due to left ventricular systolic dysfunction reduces the risk of cachexia and significant weight gain, leading to better outcomes.
Observational Study
Rigorous JournalThe association between weight-promoting medication use and weight gain in postmenopausal women: findings from the Women's Health Initiative
Antidepressants, beta-blockers, and insulin are associated with weight gain in postmenopausal women over a 3-year period.
Observational Study
Very Rigorous JournalAssociation between beta-blocker use and obesity in Hong Kong Chinese elders: a post-hoc analysis.
Beta-blocker use in elderly Chinese individuals is associated with a higher prevalence of overweight and obesity, questioning their use as the main antihypertensive in this population.
Observational StudyBeta-blockers, hypertension, and weight gain: the farmer, the chicken, and the egg.
Beta-blockers use is associated with a higher prevalence of obesity in elderly Cantonese-speaking Chinese individuals, but the cause and effect remain unclear.
Observational Study